Apogem Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Apogem Capital’s Portfolio LKFT Stock Details LKFT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,584	Closed	-$1.22M	–	41
2022 Q3	$1.22M	Buy	28,584 +883	+3%	+$45.2K	1.21%	17
2022 Q2	$1.55M	Buy	27,701 +98	+0.4%	+$5.81K	1.4%	13
2022 Q1	$1.71M	Buy	27,603 +1,625	+6%	+$99.5K	1.17%	13
2021 Q4	$1.43M	Buy	25,978 +6,711	+35%	+$350K	0.94%	25
2021 Q3	$1.01M	Buy	19,267 +13,734	+248%	+$815K	0.65%	47
2021 Q2	$381K	Buy	5,533 +422	+8%	+$32.2K	0.24%	130
2021 Q1	$394K	Buy	+5,111	New	+$471K	0.27%	123

Other funds holding LKFT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Apogem Capital's LKFT Position: Q4 2022 in Review

Apogem Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 28,584 shares — an estimated $1.22M sold.

Apogem Capital first reported a position in LKFT in Q1 2021 and held it in 7 quarters. The position peaked at $1.71M in Q1 2022. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

Apogem Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 28,584 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $1.22M.
Apogem Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2021 and held it in 7 quarters.
Apogem Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $1.71M in Q1 2022.
75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.